Celldex Therapeutics (CLDX) Payables (2016 - 2025)
Historic Payables for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $4.3 million.
- Celldex Therapeutics' Payables rose 28303.41% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 28303.41%. This contributed to the annual value of $3.3 million for FY2024, which is 655.41% down from last year.
- Per Celldex Therapeutics' latest filing, its Payables stood at $4.3 million for Q3 2025, which was up 28303.41% from $2.1 million recorded in Q2 2025.
- Over the past 5 years, Celldex Therapeutics' Payables peaked at $4.3 million during Q3 2025, and registered a low of $685000.0 during Q2 2021.
- In the last 5 years, Celldex Therapeutics' Payables had a median value of $2.3 million in 2022 and averaged $2.3 million.
- Over the last 5 years, Celldex Therapeutics' Payables had its largest YoY gain of 33155.51% in 2024, and its largest YoY loss of 6893.47% in 2024.
- Quarter analysis of 5 years shows Celldex Therapeutics' Payables stood at $1.2 million in 2021, then surged by 171.99% to $3.3 million in 2022, then rose by 4.61% to $3.5 million in 2023, then dropped by 6.55% to $3.3 million in 2024, then surged by 30.69% to $4.3 million in 2025.
- Its last three reported values are $4.3 million in Q3 2025, $2.1 million for Q2 2025, and $3.4 million during Q1 2025.